DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP 50 MG
DIPHENHYDRAMINE HYDROCHLORIDE : 50 MG · DIN 02369567 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP?
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP 50 MG contains DIPHENHYDRAMINE HYDROCHLORIDE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02369567, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 13-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP used for?
Antiallergic, antiemetic and antispasmodic actions where prompt action is necessary and oral therapy would be inadequate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02369567 |
|---|---|
| Brand name | DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP |
| Generic / active ingredient | DIPHENHYDRAMINE HYDROCHLORIDE : 50 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 50 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Ethical |
| ATC code | R06AA02 DIPHENHYDRAMINE |
| AHFS class | 04:04.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Dec-2024 |
| Original market date | 2012-02-17 00:00:00 |
How is it administered?
Adults: 10-50 mg IV or deep IM; max 400 mg/day in acute cases. Children: 5 mg/kg/24 hours or 150 mg/m2/24 hours (max 300 mg/day) in 4 divided doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store vials at room temperature (15 °C to 30 °C). Protect from freezing and light.
How is it supplied?
Preservative free 1 mL single use vials, trays of 25.
Contraindications
Avoid subcutaneous or perivascular injection. Single parenteral dosage greater than 100 mg should be avoided in hypertension and cardiac disease.
Warnings and precautions
Caution against operating vehicles/machinery. Use with caution in patients with history of asthma. Avoid single doses >100 mg in hypertension/cardiac disease.
Is DIPHENHYDRAMINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 17 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP
What can be used instead?
Other Canadian products sharing ATC code R06AA02 DIPHENHYDRAMINE. 51 of 183 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALLERGY FORMULA | 12.5 MG / 5 ML | SOLUTION | JUNO OTC INC | MARKETED | DIN 02465108 |
| ALLERGY FORMULA | 25 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02229492 |
| ALLERGY FORMULA CAPLETS | 25 MG | TABLET | PERRIGO INTERNATIONAL | MARKETED | DIN 02141728 |
| ALLERGY FORMULA CAPLETS | 25 MG | TABLET | SIGMA LIFE SCIENCES INC. | MARKETED | DIN 02479710 |
| ALLERGY FORMULA EXTRA STRENGTH | 50 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02490943 |
| ALLERGY FORMULA LIQUID CAPSULES | 25 MG | CAPSULE | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02306352 |
| ALLERNIX | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02097583 |
| ALLERNIX EXTRA STRENGTH | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02097575 |
| BENADRYL ALLERGY | 25 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02017849 |
| BENADRYL ALLERGY LIQUID | 12.5 MG / 5 ML | SOLUTION | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02019736 |
Who else supplies DIPHENHYDRAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DIPHENHYDRAMINE appears in 57 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.